Snowden Capital Advisors’s BridgeBio Pharma BBIO Stock Holding History

Snowden Capital Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19	Closed	–	–	1128
2021 Q4	$0	Buy	+19	New	+$804	﹤0.01%	2047

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Snowden Capital Advisors's BBIO Position: Q1 2022 in Review

Snowden Capital Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 19 shares.

Snowden Capital Advisors first reported a position in BBIO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

Snowden Capital Advisors reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 19 BridgeBio Pharma shares in Q1 2022.
Snowden Capital Advisors first reported a position in BridgeBio Pharma in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's BridgeBio Pharma position peaked at $0 in Q4 2021.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.